UnitedHealth Group (UNH) saw a decline in its stock price on Wednesday and Thursday, following a higher core inflation reading for the week and perceived electoral victory for Vice President Kamala Harris in Tuesday’s presidential debate. Despite this, the Dow Jones Industrial Average (DJIA), in which UNH holds a significant position, remained steady on Thursday, while the S&P 500 and NASDAQ saw gains.
Analysts have mixed opinions on how a potential Trump presidency would impact UnitedHealth stock. UBS believes that UNH would benefit from a Republican “red sweep” of the election, but the odds of this happening may have decreased following Trump’s debate performance. On the other hand, Oppenheimer remains bullish on UnitedHealth, despite choosing competitor Humana as its preferred health insurer for a Trump presidency. Overall, Oppenheimer views UnitedHealth as exhibiting the strongest trend in the managed care sub-industry, with a $650 price target.
The August Consumer Price Index (CPI) report released on Wednesday showed a slight increase in core inflation, primarily driven by rising housing costs. This news, combined with market expectations of a 25 basis point interest rate cut from the Federal Reserve, may have contributed to the decline in UnitedHealth stock. Additionally, the Biden administration’s new rules for private health care plans, aimed at improving access to mental health services, could potentially increase insurer costs.
Despite the recent dip in stock price, UnitedHealth remains in an overall healthy uptrend since early July. The stock is currently above its 50-day Simple Moving Average (SMA) of around $565. While the Moving Average Convergence Divergence (MACD) indicator is bearish, UNH stock is expected to regain its composure unless it falls below recent support levels at $557. Investors should monitor these levels for potential changes in stock performance.
In conclusion, UnitedHealth stock has experienced some fluctuations in price due to various factors, including core inflation data, election prospects, and new health care regulations. Analyst opinions vary regarding the potential impact of a Trump presidency on UNH stock, with some believing it would benefit while others prefer competitor Humana. Despite these uncertainties, UnitedHealth remains in a positive uptrend and is expected to recover from recent declines. Investors should continue to monitor market trends and company developments for potential opportunities in UNH stock.
